MutyperR

PANAMutyper™ R technology is based on peptide nucleic acid (PNA)-mediated real-time PCR clamping and melting peak analysis technology. By using wild type DNA specific PNA clamp probe, the amplification of the wild type DNA is suppressed. In addition, by using mutant type DNA specific PNA detection probe which has fluorescent dye and quencher, a single mutation can be genotyped by melting peak analysis.
Therefore, PANAMutyper™ R technology can detect a single base mutation accurately with high sensitivity for only a minute amount of mutant type DNA, such as the samples from blood. It is also very fast and convenient method for detecting mutant.

Smelt Principle

Smelt Result

Detection Content

Lung cancer is a metastatic cancer which the cancer cells are developed in the bronchial tubes or alveoli and grow along the blood vessel or lymphatic vessel. There are two types of lung cancer based on the sizes and shape of the cancer cell; non-small cell lung cancer (NSCLC) takes 75% and small cell lung cancer takes 25%. Usually, it is hard to find lung cancer in the early stage and is diagnosed as lung cancer when it is already progressed. So the prognosis tends to be bad. It is known that the patients with EGFR mutation show very high drug responses against EGFR tyrosine kinase inhibitor (TKI) such as Gefitinib (Iressa, AstraZenca) and Erlotinib (Tarceba, Roche). We expect that genotyping EGFR genes of the lung cancer patients enables predicting drug response before treatment and this will lead effective lung cancer treatment.

PANAMutyper™ R EGFR

Product NameCat No.Size
PANAMutyper™ R EGFR (47 Mutations)PNAR-300124 tests

EGFR Mutation Details

No.ReagentExonAmino Acid ChangeNucleotide changeCosmic No.
1G719E18G719Ac.2156G>C6239
2G719Sc.2155G>A6252
3G719Cc.2155G>T6253
4E19del A19p.E746_A750delc.2235_2249 del 156223
5p.E746_A750delc.2236_2250 del 156225
6p.E746_T751>IPc.2235_2251>AATTC13552
7p.K745_E749delc.2233_2247 del 1526038
8p.E746_T751>Ic.2235_2252 AAT (complex)13551
9p.E746_A750delc.2235_2248>AATTC13550
10p.L747_S752>Qc.2239_2256>CAA12403
11p.S752_I759delc.2253_2276 del 2412416
12p.E746_T751>VAc.2237_2253>TTGCT 12422
13p.E746_T751>Ac.2237_2251 del 1512678
14p.L747_T751delc.2239_2253 del 156254
15p. L747_T751delc.2238_2252 del 1523571
16p.L747_T751>Qc.2238_2252>GCA(complex)12419
17E19del B19p.L747_T751delc.2240_2254 del 1512369
18p.L747_T751delc.2239_2253 del 156254
19p.E746_T751>Vc.2237_2252>T12386
20p.E746_S752>Ic.2235_2255>AAT12385
21p.L747_T751delc.2238_2252 del 1523571
22p.E746_T751delc.2236_2253 del 1812728
23p.E746_S752>Ac.2237_2254 del 1812367
24p.E746_S752>Vc.2237_2255>T (complex)12384
25p.E746_S752>Dc.2238_2255 del 186220
26p.L747_A750>Pc.2238_2248>GC(complex)12422
27p.L747_E749delc.2239_2247 del 96218
28p.L747_S752delc.2239_2256 del 186255
29p.L747_ A750>Pc.2239_2248 TTAAGAGAAG>C12382
30p.L747_P753>Qc.2239_2258>CA(complex)12387
31p.L747_T751>Sc.2240_2251 del 126210
32p.L747_P753>Sc.2240_2257 del 1812370
33p.L747_T751>Pc.2239_2251>C(complex)12383
34p.E746_P753>VSc.2237_2257>TCT18427
35S768I20S768Ic.2303G>T6241
36T790M20T790Mc.2369C>T6240
37E20ins A20p.D770_N771insGc.2310_2311 insGGT12378
38p.P772_H773insTTPc.2315_2316 insGACAACCCC 
39p.P772_H773insGNPc.2315_2316 insGGGCAACCC 
40p.V769_N770insASVc.2309_2310 AC>CCAGCGTGGAT13558
41E20ins B20p.V769_D770insASVc.2307_2308 ins GCCAGCGTG12376
42p.H773_V774insHc.2319_2320 insCAC12377
43p.H773Lc.2318 A>T13005
44p.H773_V774insPHc.2319_2320 insCCCCAC12380
45p.V774_C775insHVc.2321_2322 insCCACGT18432
46p.D770_N771insSVDc.2311_2312 ins GCGTGGACA13428
47L858R21L858Rc.2573T>G6224
48L858Rc.2573_2574 TG>GT12429
49L861QL861Qc.2582T>A6213

KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, biliary tract cancer and thyroid cancer. The existence of KRAS mutations is often related with a prognostic marker to drug response. For example, KRAS mutation is considered a strong prognostic marker for drug response of tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva).Recently, KRAS mutation is often detected in colorectal cancer and may be related with drug responseto Cetuximab (Erbitux) or Panitumumab (Vectibix) that is used for colon cancer therapy. Therefore,examination of KRAS mutation is needed to determine drug resistance of patients with colorectal or lung cancers and will be helpful for cancer therapies.

PANAMutyper™ R KRAS

Product NameCat No.Size
PANAMutyper™ R KRAS (29 Mutations)PNAR-100124 tests

KRAS Mutation Details

No.ReagentCodonAmino Acid ChangeNucleotide changeCosmic No.
1KC12a

12

p.G12Ac.35G>C522
2p.G12Vc.35G>T520
3p.G12Rc.34G>C518
4p.G12Cc.34G>T516
5KC12bp.G12Dc.35G>A521
6p.G12Sc.34G>A517
77

13

p.G13Ac.38G>C533
8p.G13Vc.38G>T534
9p.G13Rc.37G>C529
10p.G13Cc.37G>T527
11KC13bp.G13Dc.38G>A532
12p.G13Sc.37G>A528
13KC5959p.A59Tc.175G>A546
14p.A59Ec.176C>A547
15p.A59Gc.176C>G28518
16KC6161p.Q61Kc.181C>A549
17p.Q61Ec.181C>G550
18p.Q61Pc.182A>C551
19p.Q61Rc.182A>G552
20p.Q61Lc.182A>T553
21p.Q61Hc.183A>C554
22p.Q61Hc.183A>T555
23KC117117p.K117Ec.349A>G1360831
24p.K117Nc.351A>C19940
25p.K117Nc.351A>T28519
26KC146146p.A146Tc.436G>A19404
27p.A146Pc.436G>C19905
28p.A146Gc.437C>G1360829
29p.A146Vc.437C>T19900

NRAS mutation is found in several cancers such as melanoma (13~25%), colorectal cancer (1~6%), lung cancer (1%), thyroid cancer (7%) and hepatocellular carcinoma (10%). It is know that the drug response against colorectal cancer medicine such as Erbitux and Cetuximab decreased and the prognosis of the metastatic colorectal cancer patient is bad if the patient has NRAS mutation. Recently, there are some papers that report the drug responses can be different for the NRAS mutation type so it is important to genotype each mutation. NRAS gene mutation genotyping test is necessary especially for predicting the drug sensitivity and prognosis. This test expected to play a major role for predicting the treatment of the patients and prognosis.

PANAMutyper™ R NRAS

Product NameCat No.Size
PANAMutyper™ R NRAS (31 Mutations)PNAR-110124 tests

NRAS Mutation Details

No.ReagentCodonAmino Acid ChangeNucleotide changeCosmic No.
1NC12a

12

p.G12Ac.35G>C565
2p.G12Vc.35G>T566
3p.G12Rc.34G>C561
4p.G12Cc.34G>T562
5NC12bp.G12Dc.35G>A564
6p.G12Sc.34G>A563
7NC13a13p.G13Ac.38G>C575
8p.G13Vc.38G>T574
9p.G13Rc.37G>C569
10p.G13Cc.37G>T570
11NC59p.G13Dc.38G>A573
12p.G13Sc.37G>A571
13NC5959p.A59Tc.175G>A578
14p.A59Dc.176C>A253327
15p.A59Ac.177T>C1332932
16NC6161p.Q61Rc.182A>G584
17p.Q61Kc.181C>A580
18p.Q61Lc.182A>T583
19p.Q61Hc.183A>T585
20p.Q61Hc.183A>C586
21p.Q61Pc.182A>C582
22p.Q61Ec.181C>G581
23NC117117p.K117Ec.349A>G 
24p.K117Rc.350A>G 
25p.K117Nc.351G>C 
26p.K117Nc.351G>T 
27NC146146p.A146Tc.436G>A27174
28p.A146Pc.436G>C 
29p.A146Sc.436G>T 
30p.A146Vc.437C>T4170228
31p.A146Gc.437C>G 

Please email the quote request to order@pnabio.com or click "Inquire" button below.

Catalog No Product Name Description Size Price
PNAR-1001 PANAMutyper™ R KRAS MutyperR for KRAS 29 mutations 24 testsinquire
PNAR-1101 PANAMutyper™ R NRAS MutyperR for NRAS 31 mutations 24 tests inquire
PNAR-3001 PANAMutyper™ R EGFR MutyperR for EGFR 47 mutations 24 tests inquire

© 2016 PNA BIO INC All Rights Reserved | "We Guarantee Excellent Quality for All Our Products"

Contact Us

1-844-846-0454 (Toll Free)
1-805-277-0629 (Fax)
Submit inquiry

Our Location

Address : 3541 Old Conejo Rd #112, Newbury Park, CA 91320

1-844-846-0454, 1-805-504-2220

1-805-277-0629